{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:19:52Z","timestamp":1792027192175,"version":"4.4.0"},"reference-count":5,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2019,3,1]]},"DOI":"10.1001\/jamapsychiatry.2018.3990","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T15:36:00Z","timestamp":1547048160000},"page":"337","source":"Crossref","is-referenced-by-count":154,"title":["Association of Combined Naltrexone and Ketamine With Depressive Symptoms in a Case series of Patients With Depression and Alcohol Use Disorder"],"prefix":"10.1001","volume":"76","author":[{"given":"Gihyun","family":"Yoon","sequence":"first","affiliation":[{"name":"Department of Psychiatry, VA Connecticut Healthcare System, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismene L.","family":"Petrakis","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, VA Connecticut Healthcare System, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Krystal","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, VA Connecticut Healthcare System, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"yld180009r1","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","article-title":"A consensus statement on the use of ketamine in the treatment of mood disorders.","volume":"74","author":"Sanacora","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"yld180009r2","article-title":"Attenuation of antidepressant effects of ketamine by opioid receptor antagonism","author":"Williams","journal-title":"Am J Psychiatry"},{"key":"yld180009r3","article-title":"Is there really nothing new under the sun? is low-dose ketamine a fast-acting antidepressant simply because it is an opioid?","author":"George","journal-title":"Am J Psychiatry"},{"issue":"8","key":"yld180009r4","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1038\/sj.npp.1300994","article-title":"Potentiation of low dose ketamine effects by naltrexone: potential implications for the pharmacotherapy of alcoholism.","volume":"31","author":"Krystal","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"yld180009r5","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/00000542-199901000-00023","article-title":"Stereoselective interaction of ketamine with recombinant mu, kappa, and delta opioid receptors expressed in Chinese hamster ovary cells.","volume":"90","author":"Hirota","year":"1999","journal-title":"Anesthesiology"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamapsychiatry\/article-pdf\/76\/3\/337\/17330477\/jamapsychiatry_yoon_2019_ld_180009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T13:41:21Z","timestamp":1551879681000},"score":1,"resource":{"primary":{"URL":"http:\/\/archpsyc.jamanetwork.com\/article.aspx?doi=10.1001\/jamapsychiatry.2018.3990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":5,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2018.3990","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3,1]]}}}